Spinal fluid DNA test could personalize brain cancer therapy

This study explores whether analyzing tumor DNA in cerebrospinal fluid can help doctors make better treatment decisions for people with malignant brain tumors or brain metastases from lung or breast cancer. Participants undergo a standard spinal tap or fluid collection, and the fluid is tested with a special DNA assay alongside usual methods. The goal is to see if this test improves how well the disease is controlled in the central nervous system over six months, while also monitoring safety. The results could lead to more personalized and timely treatments for these serious conditions.